2月26日,复星医药(600196/02196)发布公告,控股子公司苏州二叶制药有限公司近日获得国家药品监督管理局批准,上市药品为复方匹可硫酸钠颗粒。该药品主要用于结肠镜检查、X射线检查前的肠道清洁准备,并在必要时用于外科手术前的肠道清洁。药品的规格为每袋含匹可硫酸钠10mg、氧化镁3.5g和无水枸橼酸12g,注册分类为化学药品3类。截至2025年1月,本集团针对该药品的累计研发投入约为853万元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.